Amarantus Bioscience Holdings, Inc. Form 4 November 20, 2014

November 2	0, 2014											
FORM 4 UNITED STATES SECURITIES AND EXCHANCE COMMISSION								OMB APPROVAL				
Washington, D.C. 20549									OMB Number:	3235-0287		
Check th if no long					Expires:	January 31,						
subject to Section 1 Form 4 c	o STATE 16. or	STATEMENT OF CHANGES IN BENEFICIAL OWNE SECURITIES							Estimated a burden hou response			
Form 5 obligations may continue.Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 19401(b).30(h) of the Investment Company Act of 1940												
(Print or Type ]	Responses)											
1. Name and Address of Reporting Person <u>*</u> FARRELL ROBERT EDWARD			2. Issuer Name <b>and</b> Ticker or Trading Symbol					5. Relationship of Reporting Person(s) to Issuer				
	Amaran [AMBS		cience Hol	dings	s, Inc.	(Check all applicable)						
(Last)	(First)	(Middle)		of Earliest Ti Day/Year)	ransaction			X Director X Officer (give below)		Owner er (specify		
655 MONTGOMERY STREET, 11/19 SUITE 900				2014			I	CFO				
(Street) 4. If			4. If Ame	. If Amendment, Date Original				6. Individual or Joint/Group Filing(Check				
Filed(Mo				· · · · · · · · · · · · · · · · · · ·				Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting				
SAN FRAN	ICISCO, CA 94	111					i	Person	ore than One Re	porting		
(City)	(State)	(Zip)	Tab	le I - Non-I	Derivative S	ecurit	ies Acqu	ired, Disposed of,	or Beneficial	ly Owned		
1.Title of Security (Instr. 3)	2. Transaction Da (Month/Day/Year)		n Date, if	Code (Instr. 8)	omr Disposed (Instr. 3, 4	d of (D and 5) (A) or	))	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
Common Stock	11/19/2014			Code V P	Amount 133,333	(D) A	Price \$ 0.075	133,333	D			

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactio Code (Instr. 8)	5. onNumber of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		ate	Secur	int of rlying	8. Price of Derivative Security (Instr. 5)	9. Nu Deriv Secu Bene Own Follo Repo Trans (Instr
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		

## Edgar Filing: Amarantus Bioscience Holdings, Inc. - Form 4

## **Reporting Owners**

Reporting Ov	Relationships						
1. 8.	Director	10% Owner	Officer	Other			
FARRELL ROBER 655 MONTGOMER SAN FRANCISCO,	Х		CFO				
Signatures							
/s/ Robert Farrell	11/20/2014						
<u>**</u> Signature of Reporting Person	Date						

## **Explanation of Responses:**

\* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.